Incomplete response of infl ammatory arthritis to blockade is associated with the Th17 pathway

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1741-1748

  Alzabin, Saba ^a   Abraham, Sonya M ^b   Taher, Taher E ^c   Palfreeman, Andrew ^a   Hull, Dobrina ^a   McNamee, Kay ^a   Jawad, Ali ^c   Pathan, Ejaz ^a   Kinderlerer, Anne ^d   Taylor, Peter C ^a   Williams, Richard ^a   Mageed, Rizgar ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CELL CYCLE; CELL ISOLATION; CELL POPULATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LONGITUDINAL STUDY; MALE; MONOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TARGET CELL; TH1 CELL; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ARTHRITIS; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-17; LONGITUDINAL STUDIES; MALE; MICE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866074216     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201024     Document Type: Article

References (21)

1. Notley CA, Inglis JJ, Alzabin S, et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205:2491-7.
2. Eliçabe RJ, Cargnelutti E, Serer MI, et al. Lack of TNFR p55 results in heightened expression of IFN-γ and IL-17 during the development of reactive arthritis. J Immunol 2010;185:4485-95.
3. Murphy CA, Langrish CL, Chen Y, et al . Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003;198:1951-7. (Pubitemid 38032126)
4. Alzabin S, Williams RO. Effector T cells in rheumatoid arthritis: lessons from animal models. FEBS Lett 2011;585:3649-59.
5. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85.
6. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009;60:1647-56.
7. Inglis JJ, Simelyte E, McCann FE, et al. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008;3:612-8. (Pubitemid 351516757)
8. Inglis JJ, Criado G, Medghalchi M, et al. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther 2007;9:R113.
9. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89:9784-8.
10. Aerts NE, De Knop KJ, Leysen J, et al. Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 2010;49:2264-72.
11. http://www3.appliedbiosystems.com/cms/groups/mcb-support/documents/ generaldocuments/cms-042380.pdf (Accessed 14 April 2012).
12. Evans HG, Gullick NJ, Kirkham BW, et al. TNF-alpha antagonist therapy leads to an expansion of IL-17 expressing CD4+ T cells both in vitro and in vivo. Arthritis Rheum 2010;62:S769.
13. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinfl ammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998;160:3513-21. (Pubitemid 28164746)
14. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage infl ammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001;167:6015-20. (Pubitemid 33062800)
15. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, et al. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis 2002;61:870-6.
16. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in infl ammation processes. Arthritis Rheum 2001;44: 2176-84. (Pubitemid 33644063)
17. Herman S, Zurgil N, Machlav S, et al. Distinct effects of anti-tumor necrosis factor combined therapy on TH1/TH2 balance in rheumatoid arthritis patients. Clin Vaccine Immunol 2011;18:1077-82.
18. Koenders MI, Marijnissen RJ, Devesa I, et al. TNF/IL-17 interplay induces S100A8, IL-1beta, and MMPs, and drives irreversible cartilage destruction in vivo: rationale for combination treatment during arthritis. Arthritis Rheum 2011;8:2329-39.
19. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39.
20. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial infl ammation and bone resorption in an ex vivo model. Arthritis Rheum 2001;44:1293-303. (Pubitemid 32537527)
21. Granet C, Maslinski W, Miossec P. Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinfl ammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res Ther 2004;6:R190-8.